Clinical and experimental dermatology
-
Clin. Exp. Dermatol. · Jun 2009
Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Efalizumab is approved by the European Medicines Evaluation Agency for the treatment of adult patients with moderate to severe plaque psoriasis who fail to respond to, have a contraindication for, or cannot tolerate other systemic therapies. ⋯ Efalizumab is an effective and safe treatment for psoriasis in most patients of a high need population in routine practice, and provides maintained improvement in 'responders'. Combination treatment was transiently used in 48.4% of patients to optimize therapeutic results. Special consideration must be given to possible rebound in patients with an inadequate response or after discontinuation of treatment.
-
Clin. Exp. Dermatol. · Jun 2009
Letter Review Case ReportsHerpes zoster complicated by delayed intracranial haemorrhage.